What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Why mRNA Is Important: Structure, Function, and Clinical Impact

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to mRNA: The Messenger of Genetic Information

Messenger RNA (mRNA) is the single-stranded ribonucleic acid molecule that carries genetic information from DNA in the nucleus to ribosomes in the cytoplasm, where it directs protein synthesis. It is the essential intermediary that converts the language of nucleic acids (nucleotide sequences) into the language of proteins (amino acid sequences). Without mRNA, the genetic information stored in DNA would remain inert, inaccessible to the translational machinery that builds every protein in every living cell.

What Is mRNA?

mRNA is a polymer of ribonucleotides—adenine, guanine, cytosine, and uracil—linked by phosphodiester bonds between the 5' phosphate of one nucleotide and the 3' hydroxyl of the next. Unlike DNA, mRNA is typically single-stranded, contains ribose rather than deoxyribose, and uses uracil in place of thymine. A mature eukaryotic mRNA molecule consists of several distinct regions: a 5' cap, a 5' untranslated region (5' UTR), a coding sequence (CDS) that specifies the protein, a 3' untranslated region (3' UTR), and a poly-A tail. Each of these elements contributes to the property of mRNA that makes it a functional, translatable template rather than a passive copy of DNA.

The coding sequence is organized into triplets of nucleotides called codons. Each codon specifies one of 20 amino acids or a stop signal. Because there are 64 possible codons but only 20 amino acids, the genetic code is degenerate—most amino acids are encoded by multiple codons. The reading frame, established by the start codon AUG, determines how the nucleotide sequence is grouped into codons; a shift of one or two nucleotides changes the entire protein product.

Historical Context

The concept of an intermediary between DNA and protein emerged in the 1950s. In 1957, Francis Crick articulated the "central dogma" of molecular biology: DNA makes RNA makes protein. The term "messenger RNA" was coined in 1960 by François Jacob and Jacques Monod, who proposed that a short-lived RNA molecule transmits information from genes to ribosomes. In 1961, Sydney Brenner, François Jacob, and Matthew Meselson provided experimental evidence by showing that phage infection of E. coli induces the synthesis of a new, unstable RNA species that associates with pre-existing ribosomes. That same year, Marshall Nirenberg and Heinrich Matthaei deciphered the first codon—UUU encodes phenylalanine—using a cell-free translation system. The subsequent elucidation of the entire genetic code by Nirenberg, Har Gobind Khorana, and Robert Holley, who won the Nobel Prize in 1968, established mRNA as the central template for protein synthesis.

mRNA Structure and Its Functional Significance

Mature eukaryotic mRNA is not a naked RNA strand. It carries chemical modifications and associated proteins that determine its stability, translatability, and localization. Understanding these structural features is essential because they directly explain why mRNA is important in both normal physiology and therapeutic applications.

5' Cap and 3' Poly-A Tail

The 5' cap is a modified guanosine nucleotide linked to the first transcribed nucleotide via an unusual 5'-to-5' triphosphate bridge. The cap is added co-transcriptionally in three steps: a phosphatase removes the terminal phosphate, a guanylyltransferase adds GMP, and a methyltransferase adds a methyl group to the N7 position of guanine, producing 7-methylguanosine (m⁷G). In higher eukaryotes, additional methylations occur on the 2'-O positions of the first two ribose sugars, forming the cap-1 and cap-2 structures.

The 5' cap serves four critical functions. First, it protects the mRNA from 5'-to-3' exonucleases, which would otherwise degrade the transcript. Second, it is recognized by the cap-binding complex (CBC) and later by eukaryotic initiation factor 4E (eIF4E), which recruits the ribosome to initiate translation. Third, it marks the transcript as "self" to the innate immune system, preventing activation of RNA sensors such as RIG-I. Fourth, it facilitates splicing and nuclear export by recruiting the CBC and associated factors.

The 3' poly-A tail is a stretch of 50–250 adenine residues added post-transcriptionally by poly(A) polymerase, which does not require a DNA template. The tail is bound by poly(A)-binding proteins (PABPs), which protect the 3' end from exonucleolytic degradation and promote translation by interacting with eIF4G, bridging the 5' cap and the 3' tail in a circular "closed-loop" structure. This circularization enhances translation efficiency and coordinates the two ends of the mRNA. The length of the poly-A tail correlates with mRNA stability: longer tails generally confer longer half-lives, although the relationship is not strictly linear. The mRNA stability of a transcript is a major determinant of its steady-state abundance and, consequently, of protein output.

Untranslated Regions (UTRs)

The 5' UTR lies between the cap and the start codon. It typically ranges from 100 to 200 nucleotides in length and contains regulatory elements that influence translation initiation. A key feature is the Kozak consensus sequence (gccRccAUGG in vertebrates), which surrounds the start codon and optimizes ribosome recognition. Some 5' UTRs contain upstream open reading frames (uORFs) that can repress translation of the main coding sequence by causing premature termination or ribosome stalling. Others contain internal ribosome entry sites (IRES) or RNA secondary structures that modulate initiation.

The 3' UTR is the region between the stop codon and the poly-A tail. It is frequently longer than the 5' UTR and is a major hub for post-transcriptional regulation. The 3' UTR contains binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that control mRNA stability, localization, and translation. For example, the AU-rich elements (AREs) in the 3' UTRs of many cytokine and proto-oncogene mRNAs promote rapid deadenylation and decay, allowing tight temporal control of protein expression. The 3' UTR also contains localization signals, such as the zipcode sequences that direct β-actin mRNA to the leading edge of migrating fibroblasts.

The Journey from Transcription to Translation

The life of an mRNA molecule is a multistep journey from the nucleus to the cytoplasm, involving synthesis, processing, quality control, export, and translation. Each step is highly regulated and can be targeted by the cell to modulate gene expression.

Transcription and Processing

Transcription of protein-coding genes is carried out by RNA polymerase II (Pol II) in the nucleus. The enzyme unwinds the DNA double helix and synthesizes a complementary RNA strand in the 5'-to-3' direction, using the template strand of DNA. Transcription initiates at a promoter region, typically containing a TATA box or initiator element, and proceeds through the gene body until a polyadenylation signal (AAUAAA) is encountered downstream of the coding sequence.

Pre-mRNA undergoes three essential processing steps before it becomes mature mRNA, collectively referred to as mRNA processing:

Capping occurs when the transcript is approximately 20–30 nucleotides long. The cap is added to the 5' end and is retained throughout the mRNA's life.
Splicing removes introns—non-coding intervening sequences—and joins exons. This is catalyzed by the spliceosome, a large ribonucleoprotein complex composed of five small nuclear RNAs (U1, U2, U4, U5, U6) and more than 100 proteins. The spliceosome recognizes the 5' splice site (GU), the branch point (A), and the 3' splice site (AG), and performs two transesterification reactions to excise the intron as a lariat structure. Alternative splicing allows a single gene to produce multiple mRNA isoforms, dramatically expanding the proteome. For example, the DSCAM gene in Drosophila can generate over 38,000 distinct mRNA isoforms through alternative exon selection.
Polyadenylation occurs when the pre-mRNA is cleaved 10–30 nucleotides downstream of the AAUAAA signal, and poly(A) polymerase adds 50–250 adenine residues. The cleavage and polyadenylation are coupled to transcription termination.

Nuclear Export and Ribosome Binding

Mature mRNA is exported from the nucleus through nuclear pore complexes (NPCs) by the transcription–export (TREX) complex and the export receptor NXF1–NXT1. Export is directional and requires that the mRNA be properly processed; unspliced or improperly capped transcripts are retained and degraded by the nuclear exosome. During export, the mRNA is coated with RNA-binding proteins that form a messenger ribonucleoprotein (mRNP) particle, protecting it from nucleases and preparing it for translation.

Once in the cytoplasm, the mRNA must be translated by ribosomes. Translation occurs in three phases:

Initiation: The 43S pre-initiation complex, consisting of the 40S ribosomal subunit, eIF2-GTP-Met-tRNAᵢ, and several initiation factors, binds to the 5' cap via eIF4F (composed of eIF4E, eIF4G, and eIF4A). The complex scans the 5' UTR in a 5'-to-3' direction until it encounters the start codon AUG in a favorable Kozak context. GTP hydrolysis triggers the joining of the 60S subunit to form the 80S ribosome.
Elongation: Aminoacyl-tRNAs enter the A site of the ribosome in a codon-dependent manner, peptide bonds are formed in the peptidyl transferase center, and the ribosome translocates processively along the mRNA. Elongation factors eEF1A and eEF2 facilitate this process, consuming GTP.
Termination: When a stop codon (UAA, UAG, or UGA) enters the A site, release factors eRF1 and eRF3 promote hydrolysis of the peptidyl-tRNA bond, releasing the completed polypeptide and dissociating the ribosome.

The translatability of mRNA sequences depends on multiple features: codon optimality, secondary structure in the 5' UTR, the Kozak context, and the availability of cognate tRNAs. Codons that match abundant tRNAs are translated faster and more accurately, whereas rare codons can cause ribosome stalling and co-translational protein degradation.

mRNA in Gene Expression Regulation

The steady-state level of a protein is determined not only by the rate of transcription but also by the abundance and translatability of its mRNA. Cells exploit multiple layers of regulation to fine-tune gene expression, and mRNA is a central node in this regulatory network.

Transcriptional Control

The primary control point for gene expression is the rate of transcription initiation. Transcription factors bind to enhancers and promoters, recruiting co-activators such as the Mediator complex and chromatin remodelers that open the DNA for Pol II access. The rate of transcription can vary by orders of magnitude between genes and can be rapidly induced or repressed in response to signals. For example, the MYC proto-oncogene is transcriptionally induced within minutes of growth factor stimulation, leading to a surge of MYC mRNA that drives cell proliferation.

However, transcriptional control alone cannot explain the dynamic range of protein expression. Many genes are transcribed at similar rates but produce vastly different amounts of protein because of differences in mRNA stability and translation efficiency. The half-life of mRNA ranges from minutes (e.g., c-FOS, ~15 minutes) to hours (e.g., β-globin, >24 hours), and this variation is largely determined by sequences in the 3' UTR and by the activity of decay pathways.

Post-Transcriptional Regulation

Post-transcriptional regulation operates on existing mRNA molecules and can produce rapid changes in protein output without altering transcription. The major mechanisms include:

MicroRNA-mediated silencing: miRNAs are ~22-nucleotide non-coding RNAs that base-pair with complementary sequences in the 3' UTR of target mRNAs. Perfect or near-perfect complementarity leads to mRNA cleavage by the RNA-induced silencing complex (RISC), whereas partial complementarity causes translational repression and deadenylation. A single miRNA can target hundreds of mRNAs, and a single mRNA can be regulated by multiple miRNAs. For example, miR-21 is overexpressed in many cancers and targets tumor suppressor mRNAs such as PTEN and PDCD4.
RNA-binding proteins (RBPs): RBPs such as HuR, AUF1, and TTP bind to specific sequences in the 3' UTR and either stabilize or destabilize the mRNA. HuR stabilizes ARE-containing mRNAs by competing with decay factors, whereas TTP promotes their degradation by recruiting the CCR4-NOT deadenylase complex.
Nonsense-mediated decay (NMD): NMD degrades mRNAs that contain a premature termination codon (PTC), preventing the production of truncated, potentially dominant-negative proteins. NMD is triggered when the ribosome terminates more than 50–55 nucleotides upstream of the final exon-exon junction, leaving the exon-junction complex (EJC) downstream of the stop codon.
Codon optimality: mRNAs enriched in optimal codons are more stable than those with rare codons, because slow translation elongation promotes deadenylation and decay. This codon-optimality effect couples translation efficiency to mRNA stability.

These mechanisms ensure that mRNA levels are not simply a passive reflection of transcription but are actively shaped by the cell's needs. The mRNA unstable nature of many regulatory transcripts is a feature, not a bug: it allows rapid shutdown of protein production when the signal is removed.

Methods to Study mRNA: From Northern Blot to RNA-Seq

Measuring mRNA expression is fundamental to molecular biology. Several techniques are available, each with distinct advantages and limitations in terms of sensitivity, throughput, and quantitative accuracy.

Quantitative PCR (qPCR)

Quantitative reverse transcription PCR (RT-qPCR) is the gold standard for measuring the expression of a small number of genes with high sensitivity and precision. The workflow is:

RNA extraction: Total RNA is isolated using guanidinium thiocyanate-phenol-chloroform (e.g., TRIzol) or column-based kits. Typical yields from 10⁶ cultured cells are 5–20 µg of total RNA.
Reverse transcription: RNA is converted to cDNA using reverse transcriptase (e.g., M-MLV or SuperScript IV) and either oligo(dT) primers, random hexamers, or gene-specific primers. The reaction is typically performed at 42–50°C for 30–60 minutes.
PCR amplification: cDNA is amplified using gene-specific primers and a fluorescent probe (TaqMan) or intercalating dye (SYBR Green). The reaction is cycled 40 times (typically 95°C for 15 s, 60°C for 60 s) in a real-time thermal cycler.
Quantification: The cycle threshold (Ct) is the cycle at which fluorescence exceeds background. Gene expression is calculated relative to a reference gene (e.g., GAPDH, ACTB) using the ΔΔCt method: fold change = 2^(−ΔΔCt).

RT-qPCR can detect transcripts present at fewer than 10 copies per cell and can distinguish between closely related isoforms if primers are designed to span exon-exon junctions.

RNA Sequencing (RNA-Seq)

RNA-Seq uses high-throughput sequencing to profile the entire transcriptome in an unbiased manner. The standard protocol involves:

RNA isolation and quality assessment: RNA integrity is checked using an Agilent Bioanalyzer; an RNA integrity number (RIN) of ≥8 is typically required.
Library preparation: mRNA is enriched by poly-A selection (using oligo-dT magnetic beads) or by ribosomal RNA depletion. The RNA is fragmented (typically to 200–300 nucleotides), reverse transcribed to cDNA, and ligated to sequencing adapters. The library is amplified by PCR (12–15 cycles).
Sequencing: Libraries are sequenced on platforms such as Illumina NovaSeq, producing 50–150 base pair reads. A typical RNA-Seq experiment generates 20–50 million reads per sample.
Bioinformatic analysis: Reads are aligned to a reference genome or transcriptome using tools such as STAR or HISAT2. Gene expression is quantified as counts per million (CPM) or transcripts per million (TPM), and differential expression is assessed using DESeq2 or edgeR.

RNA-Seq can detect novel transcripts, splice isoforms, and allele-specific expression, and it has a dynamic range of over five orders of magnitude. However, it is more expensive and computationally intensive than qPCR, and its accuracy depends on sequencing depth and alignment quality.

Other methods include Northern blotting (size-based detection of specific mRNAs using radiolabeled or digoxigenin-labeled probes), microarrays (hybridization of labeled cDNA to gene-specific probes on a chip), and single-molecule fluorescence in situ hybridization (smFISH) for spatial localization of individual mRNA molecules in fixed cells.

mRNA in Medicine: Vaccines and Therapeutics

The importance of mRNA extends far beyond basic biology. In the 21st century, mRNA has emerged as a powerful platform for vaccines and therapeutics, culminating in the rapid development of COVID-19 vaccines.

mRNA Vaccines

mRNA vaccines deliver a synthetic mRNA encoding a pathogen antigen into host cells, which then produce the antigen and elicit an immune response. The COVID-19 vaccines from Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) encode the SARS-CoV-2 spike protein, stabilized in its prefusion conformation by two proline substitutions (K986P and V987P).

The design of therapeutic mRNA vaccines requires careful optimization of several parameters:

Nucleoside modification: Replacement of uridine with N1-methylpseudouridine (m1Ψ) reduces activation of innate immune sensors such as TLR7/8 and RIG-I, decreasing inflammation and increasing translation. This modification was critical to the success of the COVID-19 vaccines.
Codon optimization: The coding sequence is optimized for human codon usage and to remove secondary structures that impede translation.
UTR design: The 5' and 3' UTRs are engineered to enhance stability and translation. For example, the use of β-globin UTRs or synthetic UTRs with optimized regulatory elements.
Purification: In vitro transcribed mRNA is purified by high-performance liquid chromatography (HPLC) or cellulose-based methods to remove double-stranded RNA (dsRNA) contaminants, which are potent innate immune activators.
Delivery: mRNA is encapsulated in lipid nanoparticles (LNPs) composed of ionizable lipids (e.g., ALC-0315 or SM-102), phospholipids, cholesterol, and PEG-lipids. The LNPs protect the mRNA from nucleases, facilitate cellular uptake via endocytosis, and promote endosomal escape.

The difference between mRNA and non mRNA vaccine is fundamental: mRNA vaccines instruct the body's own cells to produce the antigen, whereas traditional vaccines deliver the antigen itself (protein subunit, inactivated virus) or a viral vector encoding the antigen. mRNA vaccines are faster to design, can be produced cell-free, and do not carry a risk of genomic integration.

mRNA-Based Therapies

Beyond vaccines, mRNA is being developed for a wide range of therapeutic applications:

Protein replacement therapy: mRNA encoding a missing or defective protein can be delivered to restore function. For example, mRNA encoding cystic fibrosis transmembrane conductance regulator (CFTR) is being tested for cystic fibrosis, and mRNA encoding factor VIII or IX is being developed for hemophilia.
Cancer immunotherapy: mRNA can encode tumor antigens to prime anti-tumor T cell responses, or can encode cytokines (e.g., IL-12) or costimulatory ligands to enhance anti-tumor immunity. Personalized cancer vaccines use mRNA encoding neoantigens identified by tumor sequencing.
Gene editing: mRNA encoding Cas9 or base editors can be delivered alongside guide RNAs to achieve transient, non-integrating genome editing. This approach avoids the risk of off-target integration associated with DNA-based delivery.
Reprogramming: mRNA encoding transcription factors (e.g., OCT4, SOX2, KLF4, c-MYC) can be used to generate induced pluripotent stem cells (iPSCs) without genomic integration.

The translatability of mRNA in vitro is a key consideration for manufacturing: in vitro transcription reactions using T7 or SP6 RNA polymerase typically yield 1–5 mg of mRNA per mL of reaction, and the product must be capped (using a co-transcriptional cap analog such as CleanCap or an enzymatic capping step) and polyadenylated to achieve optimal translation in vivo.

Common Pitfalls and Misconceptions About mRNA

Students frequently encounter conceptual difficulties when learning about mRNA. Addressing these misconceptions is essential for building a solid foundation.

mRNA vs. DNA

A common error is to treat mRNA as a "copy" of DNA that is structurally identical except for the sugar and one base. In reality, mRNA is a processed, modified, and regulated molecule that differs from DNA in several fundamental ways:

Single-stranded: mRNA is typically single-stranded, whereas DNA is double-stranded. This allows mRNA to be translated directly by ribosomes without unwinding.
Short-lived: mRNA is transient, with half-lives ranging from minutes to hours, whereas DNA is stable across the life of the cell.
Modified: mRNA carries a 5' cap, a 3' poly-A tail, and internal modifications such as N6-methyladenosine (m⁶A), none of which are present in DNA.
Non-genetic: mRNA is not the hereditary material; it is an intermediate that does not replicate and is not passed to daughter cells.

Another misconception is that the mRNA sequence is identical to the coding strand of DNA. In fact, mRNA is complementary to the template strand and identical (with U instead of T) to the coding strand. However, introns are removed during splicing, so the mature mRNA is shorter than the genomic sequence.

Splicing and Isoforms

Students often assume that one gene produces one mRNA and one protein. This is incorrect for most human genes. Over 95% of human multi-exon genes undergo alternative splicing, producing multiple mRNA isoforms that can encode proteins with different functions, localizations, or activities. For example, the Bcl-x gene produces two isoforms: Bcl-xL (long) is anti-apoptotic, whereas Bcl-xS (short) is pro-apoptotic. The ratio of these isoforms determines cell fate.

A related misconception is that splicing is a simple "cut and paste" of exons. In reality, splicing is a highly regulated, dynamic process that can be influenced by splicing enhancers and silencers, RNA secondary structure, and the rate of Pol II transcription. Mutations that disrupt splicing are a major cause of human genetic disease, accounting for up to 15% of disease-causing point mutations.

A third pitfall is the assumption that the start codon is always the first AUG in the mRNA. In many mRNAs, the first AUG is in a poor Kozak context and is skipped by the scanning ribosome, leading to initiation at a downstream AUG. This "leaky scanning" can produce multiple protein isoforms from a single mRNA.

Finally, students often overlook the importance of mRNA degradation. The steady-state level of mRNA is the balance between synthesis and decay, and changes in decay rate can have profound effects on protein output. For example, the rapid degradation of c-MYC mRNA (half-life ~30 minutes) allows its levels to fall quickly when transcription is shut off, whereas the stable β-globin mRNA (half-life >24 hours) ensures sustained hemoglobin production in reticulocytes.

Summary: Why mRNA Is Important for Life and Science

mRNA is the essential bridge between the genome and the proteome. It is the molecule that carries genetic information from DNA to ribosomes, where it directs the synthesis of every protein in the cell. Its structure—the 5' cap, 3' poly-A tail, UTRs, and coding sequence—is exquisitely designed to balance stability, translatability, and regulation. Its life cycle, from transcription through processing, export, and translation, is a masterpiece of coordinated molecular choreography.

mRNA is also a central node in gene expression regulation. Cells control mRNA abundance through transcriptional rates, splicing, stability, and translation, allowing precise and rapid responses to environmental signals. The study of mRNA has driven the development of powerful technologies, from Northern blots to RNA-Seq, that have transformed our understanding of biology.

Most importantly, mRNA has become a therapeutic platform. The success of mRNA vaccines against COVID-19 demonstrated that synthetic mRNA can be delivered safely and effectively to human cells, opening the door to a new class of medicines. mRNA-based therapies for cancer, genetic diseases, and protein replacement are in active development, and the property of mRNA that makes it so versatile—its ability to encode any protein—is the foundation of this revolution.

For the student of biology, understanding mRNA is not merely an academic exercise. It is the key to understanding how genes control phenotypes, how cells respond to their environment, and how we can harness the central dogma to treat disease.

Frequently Asked Questions

Why is mRNA important?

mRNA is important because it is the intermediate molecule that carries genetic information from DNA to ribosomes, where proteins are synthesized. It is the physical link between genotype and phenotype. Without mRNA, the information in DNA could not be expressed as proteins, and life as we know it would not exist. mRNA is also important in medicine, as it is the basis of mRNA vaccines and therapies.

What is the function of mRNA in protein synthesis?

mRNA functions as the template for protein synthesis. Its coding sequence is read in triplets (codons) by ribosomes, which decode the sequence into a chain of amino acids. The 5' cap and 3' poly-A tail promote translation initiation and stability, while the UTRs contain regulatory elements that control how efficiently the mRNA is translated.

How does mRNA differ from DNA?

mRNA differs from DNA in five key ways: (1) it is single-stranded, whereas DNA is double-stranded; (2) it contains ribose instead of deoxyribose; (3) it contains uracil instead of thymine; (4) it is relatively short-lived, with half-lives of minutes to hours; and (5) it carries post-transcriptional modifications (5' cap, poly-A tail, m⁶A) that DNA does not have.

What is the role of the 5' cap and poly-A tail in mRNA?

The 5' cap (7-methylguanosine) protects the mRNA from 5'-to-3' exonucleases, promotes translation initiation by binding eIF4E, facilitates nuclear export, and marks the mRNA as "self" to the innate immune system. The 3' poly-A tail protects the mRNA from 3'-to-5' degradation, promotes translation by binding poly(A)-binding proteins, and is involved in the closed-loop structure that enhances translation efficiency.

How is mRNA regulated in the cell?

mRNA is regulated at multiple levels: transcription rate (how fast it is synthesized), processing (splicing, capping, polyadenylation), nuclear export, stability (half-life), and translation efficiency. MicroRNAs and RNA-binding proteins bind to the 3' UTR to promote degradation or translational repression. Nonsense-mediated decay degrades mRNAs with premature stop codons. Codon optimality couples translation speed to mRNA stability.

Why is mRNA important in vaccines?

mRNA vaccines deliver a synthetic mRNA encoding a pathogen antigen into host cells. The cells produce the antigen, which triggers an immune response. mRNA vaccines are important because they can be designed and manufactured rapidly, do not require cell culture or viral vectors, and can be easily modified to target new variants. The COVID-19 mRNA vaccines demonstrated >90% efficacy and saved millions of lives.

What techniques are used to measure mRNA expression?

Common techniques include: RT-qPCR (quantitative, high sensitivity, for a few genes), RNA-Seq (unbiased, genome-wide, detects isoforms), Northern blotting (size-based detection), microarrays (hybridization-based, for known genes), and single-molecule FISH (spatial localization in cells). The choice of method depends on the number of genes, the required sensitivity, and the biological question.

Key Takeaways

mRNA is the essential intermediary in the central dogma, carrying genetic information from DNA to ribosomes for protein synthesis.
Mature eukaryotic mRNA has a 5' cap, 5' UTR, coding sequence, 3' UTR, and poly-A tail, each contributing to stability, translation, and regulation.
mRNA undergoes capping, splicing, and polyadenylation before export to the cytoplasm, where it is translated by ribosomes.
mRNA levels are regulated by transcription rate, splicing, stability, microRNAs, and RNA-binding proteins, allowing precise control of gene expression.
Techniques such as RT-qPCR and RNA-Seq enable quantitative measurement of mRNA expression across the transcriptome.
mRNA vaccines and therapies represent a transformative medical platform, with COVID-19 vaccines demonstrating their safety and efficacy.
Understanding mRNA structure and function is fundamental to molecular biology and to the development of next-generation medicines.